Medicines Formulary

Medicines A–Z

C

Drug name	NICE TAs	Comments
Capasal
Capecitabine tablets	TA61 - Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA100 - Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer TA191 - Capecitabine for the treatment of advanced gastric cancer TA263 - Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer TA62 - Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer
Caphosol oral rinse		Oncology and haematology only.
Caplacizumab (Cablivi®)	TA667 - Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura
Capsaicin (Zacin, Axsain)		Very high relative cost, Tier 2
Capsaicin cream 0.075%		Only strength licensed for post-herpetic neuralgia and diabetic peripheral polyneuropathy.
Captopril tablets		For existing patients only
Carbamazepine		Trigeminal neuralgia only
Carbamazepine M/R tablets		Tegretol
Carbamazepine SF liquid		Tegretol

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.